MRNA
Moderna Inc
$150.19
Earnings Summary
Revenue | $4749Mn |
Net Profits | $2197Mn |
Net Profit Margins | 46.26% |
PE Ratio | 4.95 |
Highlights
Moderna Inc’s revenue jumped 9.07% since last year same period to $4749Mn in the Q2 2022. On a quarterly growth basis, Moderna Inc has generated -21.71% fall in its revenue since last 3-months.
Moderna Inc’s net profit fell -20.97% since last year same period to $2197Mn in the Q2 2022. On a quarterly growth basis, Moderna Inc has generated -39.92% fall in its net profits since last 3-months.
Moderna Inc’s net profit margin fell -27.54% since last year same period to 46.26% in the Q2 2022. On a quarterly growth basis, Moderna Inc has generated -23.26% fall in its net profit margins since last 3-months.
Moderna Inc’s price-to-earnings ratio after this Q2 2022 earnings stands at 4.95.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Moderna Inc post its latest quarter earnings
EPS Estimate Current Quarter | 4.55 |
EPS Estimate Current Year | 4.55 |
Highlights
Moderna Inc’s earning per share (EPS) estimates for the current quarter stand at 4.55 - a -12.67% fall from last quarter’s estimates.
Moderna Inc’s earning per share (EPS) estimates for the current year stand at 4.55.
Key Ratios
Key ratios of the Moderna Inc post its Q2 2022 earnings
Earning Per Share (EPS) | 5.24 |
Return on Assets (ROA) | 0.46 |
Return on Equity (ROE) | 1.14 |
Dividend Per Share (DPS) | 0 |
Highlights
Moderna Inc’s earning per share (EPS) fell -18.89% since last year same period to 5.24 in the Q2 2022. This indicates that the Moderna Inc has generated -18.89% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Moderna Inc’s return on assets (ROA) stands at 0.46.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Moderna Inc’s return on equity (ROE) stands at 1.14.
Moderna Inc declared 0 dividend per share during the earnings announcement for Q2 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-06-30 | 4.55 | 5.24 | 15.16% |
2022-05-04 | 5.21 | 8.58 | 64.68% |
Company Information
Moderna is a pharmaceutical and biotechnological company founded in 2010 in Massachusetts, the United States, by 'Derrick Rossi', 'Timothy A. Springer', 'Robert S. Langer', 'Kenneth R. Chien', 'Noubar Afeyan'. The CEO of this company is Stephan Bancel. The company aims to provide primarily mRNA vaccines and RNA therapeutics. They use a copy of messenger RNA to create vaccines for immune response in a body. The company develops and discovers drugs capable of producing antibodies in the patient's cells. The company develops and produces human proteins, antibodies, and novel proteins using mRNA therapeutics, which helps prevent, treat, and cure disease. The only commercial product of this company right now is the Moderna COVID-19 vaccine. The Moderna Company has about twenty-three treatments and vaccine aspirants; fifteen have already been moved into the clinical trials. These vaccine aspirants consist of respiratory virus, chikungunya, single-shot COVID-19 booster, and many more. The company's therapeutic areas are infectious diseases, immuno-oncology, rare diseases, cardiovascular disease, and auto-immune disease. The company's revenue is $803.4 million, and the company's capitalisation, including cash equivalents and investments, is $12.2 billion. The company is currently developing clinical programs to create mRNA medicines for various diseases and conditions. They have made significant advancements in pioneering new vaccines and therapeutics that are capable of treating rare diseases MMA (Methylmalonic Acidemia) and PA (Propionic Acidemia) and preventing diseases like CMV (cytomegalovirus), Zika, and cancer. The company currently has twenty-three development programs and fifteen centred clinical studies. The company has developed relations with several pharmaceutical and biotechnological companies, government organisations, foundations and research institutions with experience and knowledge to fuel the project. Some of the notable companies in the Moderna portfolio include 'AstraZeneca', 'Merck', 'Vertex', 'Barda', 'Bill and Melinda Gates', 'Darpa', 'Institut Pasteur', and 'Karolinska'. Currently Moderna Inc has a market cap of $59.08 Billion. It has a P.E ratio of 3.94. The shares of Moderna Inc are trading at $134.04. .
Organisation | Moderna Inc |
Headquarters | Cambridge, Massachusetts, US |
Employees | 1.3K |
Industry | Health Technology |
CEO | Stephane Bancel |